The ongoing shortage of the pancreatic enzyme replacement therapy (PERT) Creon in the UK is causing significant worry and stress for patients, doctors, and pharmacists. The Department of Health and Social Care issued a national patient safety alert due to limited availability of active pharmaceutical ingredients and manufacturing constraints. This drug is used to treat pancreatic exocrine insufficiency in patients with cystic fibrosis, pancreatic cancer, and pancreatitis. With no clinical alternative available, patients are being left at risk. Clinicians and charities have warned about the impact of the shortage on patients and urged for solutions to ensure the availability of this important medication.
Source link
Creon: Shortages of pancreatic enzyme replacement therapy are causing “worry and stress”
